Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces Preliminary Settlement Agreement for $145 Million
Summary
Jazz Pharmaceuticals plc has entered into a preliminary class settlement agreement to resolve claims related to its patent litigation settlement agreements with generic drug manufacturers. The Company has agreed to pay a total of $140 million in a lump sum to settle claims from indirect Xyrem purchasers. The settlement is subject to court approval and is expected to result in a pre-tax charge of approximately $145 million in the first quarter of 2025. If approved, this settlement will resolve the majority of claims in the multidistrict litigation proceedings in the U.S. District Court for the Northern District of California.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement